Home / Transcripts / ALK-Abelló A/S (ALKB) · November 13, 2025

ALK-Abelló A/S (ALKB) Earnings Call Transcript

November 13, 2025

Nasdaq Copenhagen DK Health Care Pharmaceuticals earnings 39 min

Earnings Call Speaker Segments

Per Plotnikof executive
#1

Good day, everyone, and welcome as we present ALK's results for Q3 along with the outlook for the full year. We appreciate all of you being here. Let's move to slide 2, which shows the agenda and who will be speaking. I'm Per Plotnikof, and I serve as Head of Investor Relations. Joining me today are our CEO, Peter Halling, and our CFO, Claus Steensen Sølje. To begin, we'll go through a few quarterly highlights, and after that we'll take a closer look at the markets, our products, and the financials. We'll walk through some of the areas where our strategy is focused before we get into the updated outlook for the full year. As always, we'll wrap up the presentation with a Q&A session. To kick things off, I'll pass things to Peter and to slide number three. Over to you, Peter.

Peter Halling executive
#2

Thank you, Per, and thanks to everyone for being on this call. Q3 was marked by a sharp emphasis on delivering our main strategic programs: the launches of the pediatric tablet, a fresh partnership covering China, and bringing neffy to market. The reactions in the market to the children's tablet launches are genuinely encouraging. Rollout of ACARIZAX, our house dust mite tablet for children, moved ahead nicely and kept adding to the flow of new patients during Q3. Beyond that, ACARIZAX is drawing new prescribers, particularly among pediatricians, which points to the children's indications having the potential to widen ALK's addressable markets. We likewise observed encouraging early uptake of ITULAZAX, the tree tablet, for children and adolescents. In China, we signed a partnership with Grand Pharma, a solid local Chinese partner dedicated to speeding up uptake of ALK's house dust mite allergy products. Grand Pharma has already assumed sales and marketing for Alutard, our SCIT product, along with skin prick tests. That partnership is expected to turn margin accretive for ALK over the mid-term, mainly through cost savings in China together with income from product supply and upfront and milestone payments reaching as much as 1.3 billion DKK. A couple of weeks ago, we launched EURneffy, the adrenaline spray, in the UK, which is Europe's and ALK's largest anaphylaxis market.

Peter Halling executive
#3

At the same time, EURneffy is building momentum in Germany, which was our first market entry. This product came to market in July. Additional country launches are just around the corner. Though it's still quite early, the reaction from the market thus far validates the product's potential over the long term, even though traditional anaphylaxis products have long been favored in clinical practice, and we'll need to navigate that carefully. Q3 financial results came in strong, with double-digit growth across every sales region and product group. Revenue rose 18% and exceeded expectations, while earnings climbed 41% in local currencies, producing an EBIT margin of 28%. Given the Q3 outcome and what we foresee for Q4, particularly in Europe, we have revised the full-year outlook. Revenue is now projected to rise 13% to 15%, and the EBIT margin should climb to roughly 26%. We'll walk through all of this in more detail shortly, but first, Claus, I'll turn things over to you, and to slide four.

Claus Steensen Sølje executive
#4

Thanks, Peter. Now let's examine how each of our three sales regions performed. Europe, our largest region, posted 18% growth. Sales of tablets, anaphylaxis products, and SLIT-drops drove that revenue increase. To a minor extent, Q3 growth got a positive effect from some phasing of sales between Q3 and Q4. Tablet sales rose 23%, with broad-based growth across brands and markets. I should also note that we did see wholesalers holding slightly higher inventories, which could point to somewhat increasing trading patterns — something natural in a launch situation such as the one we're in with the children tablets right now. In Europe, growth in the tablet business was primarily tied to higher volumes from more patients on treatment, while prices and rebate adjustments mattered much less. New patients fueled the volume growth, with the largest contribution coming from our house dust mite patients, ACARIZAX, and the tree pollen patients, ITULAZAX. The children indications for ACARIZAX added positively across markets, while the recent launch of ITULAZAX has now begun contributing to patient inflow, particularly in the key German market. SCIT and SLIT-drops sales combined were up 7% in Europe. SLIT-drops sales kept gaining from an expansion of the patient and prescriber bases in France.

Claus Steensen Sølje executive
#5

SCIT sales got a temporary lift from one-off shifts in how patients were supplied, though the core growth remained constrained because fewer patients began treatment on our legacy products. In Europe, sales of other products rose 39%, with the anaphylaxis portfolio leading the way at 44% growth. Jext auto-injector sales benefited from solid commercial execution, including tenders newly secured in Southern European markets following recent supply problems at a competitor. Revenue also saw a modest contribution from EURneffy. Turning to North America, revenue was up 20%. The US business kept recovering from last year's stagnation, and the Canadian business maintained its growth. Tablet sales in North America climbed 20%. The pediatric indication for ODACTRA continued to fuel stronger uptake among allergists and, to a limited degree, new pediatric prescribers in the US. Canada posted higher growth, powered by sustained demand and volume increases, along with some destocking at wholesalers. North American SCIT bulk sales were up 1%, and sales of other products rose 41%, reflecting higher volumes and improved pricing for our life science products. Revenue from other products also included, as planned, a modest cost reimbursement from ARS Pharmaceuticals tied to our co-promotion agreement for neffy in the US.

Claus Steensen Sølje executive
#6

International market revenue rose 14%, driven by higher SCIT shipments into China. Shipments to China restarted in Q2 following the renewal of ALK's import license, and they carried on through Q3, so SCIT revenue in that region climbed 43%. In-market sales in China kept growing at a double-digit rate. Tablet revenue across international markets fell 4% after we reduced shipments to minor markets, whereas revenue from Japan, our primary market, held steady. In-market sales in Japan posted double-digit growth, though capacity constraints continued to keep our partner Torii from fully satisfying demand for CEDARCURE tablets. Torii's new API manufacturing facility is now ramping toward full operation, but some time will still pass before that additional capacity makes its way through the manufacturing cycle. Now let's move to a quick update on the product lines covered on slide five. Worldwide tablet revenue climbed 17%, supported by strong growth in Europe and North America and mainly fueled by higher volumes. Every brand posted double-digit growth apart from CEDARCURE, which grew modestly, as I just mentioned. Revenue from SCIT and SLIT-drops combined rose 11%, with gains across every sales region. The key growth drivers were the restart of SCIT shipments to China and very strong growth in SLIT-drops in France, our large market.

Claus Steensen Sølje executive
#7

Other products brought in 42% more revenue, and the anaphylaxis portfolio led the way with 68% growth. Jext performed strongly in markets across the board, and EURneffy added to growth as well, even at this early point in its commercial rollout. To sum up, we saw robust growth across every product line and every sales region in Q3. With those quarterly updates covered, let's turn to the year-to-date results on slide six. Revenue for the first nine months of 2025 came in above 4.5 billion Danish kroner, following 14% growth in local currencies. That growth largely mirrors higher sales of tablets and anaphylaxis products. Gross profit of 3 billion DKK produced a gross margin of 67%, a substantial rise of 3 percentage points. These improvements mirrored higher volumes and shifts in the sales mix, where European tablet sales in particular drove the positive development. We also saw solid production efficiencies coming through. The gross margin additionally received indirect support from muted tablet sales growth in international markets, which carries lower margins as a result of the Torii partnership. On top of that, at present we have only a minor contribution from the EURneffy business, which likewise carries lower gross margins than our European tablets. Capacity cost rose by 5% to 1.8 billion Danish kroner.

Claus Steensen Sølje executive
#8

During the Q2 earnings call in August, once we had raised the outlook for the entire year, we indicated our intention to use revenue that came in above expectations for additional spending on a range of growth initiatives. That is what we began to do in Q3, when R&D expenses rose 16%, and sales and marketing cost went up 3%. Even so, the increase in cost came in below plan, which means you should anticipate higher capacity cost in Q4. I will return to this point later. Operating profit, EBIT, rose 44% in local currencies to nearly 1.3 billion Danish kroner, lifting the EBIT margin to 28% from 22%. That EBIT margin gain came from greater sales, improvements in gross margin, and a modest rise in capacity cost. In addition, no one-off cost or optimizations were recognized, unlike last year, when one-offs came to 49 million Danish kroner. Free cash flow nearly doubled, reaching 836 million Danish kroner. Greater earnings more than offset investment to scale up tablet production, upgrade legacy production, and expand the anaphylaxis operation. We kept using part of the cash we generated to pay down our debt. Cash flow from financing was minus 736 million. As a result, our net debt to EBITDA ratio currently stands at minus 0.1, meaning we carry no debt at this point.

Claus Steensen Sølje executive
#9

Overall, these were strong results that further strengthened ALK's financial standing and confirmed we remain on course to meet our long-term financial targets. With that said, I'll now hand things back to you, Peter, and move to slide seven, where we'll cover the status of our key strategic initiatives.

Peter Halling executive
#10

Thanks, Claus. I'll begin with a bit more detail on the key launches of our respiratory tablets for children. In September, ACARIZAX, the house dust mite tablet, became available for children across 21 markets — 14 of them served by ALK and seven partner markets. The newer rollout of the tree tablet, ITULAZAX, for children and adolescents now spans 11 markets, and two further launches are planned for Q4. Far, key indicators keep performing strongly across metrics, including new patients, interactions with caregivers, doctor visits, sales, prescribers, etc. In September, roughly 3,000 unique prescribers in markets ALK serves directly were estimated to have prescribed at least one of the two tablets for children. That prescriber base includes new pediatricians, which shows we're gradually expanding markets. It's still early days, but the market response is encouraging. If we can sustain these trends, the pediatric indications will become a very important contributor to ALK's future growth for many years. Within respiratory allergy, things also moved forward in China. In China, we initiated a bridging trial to facilitate the approval of ACARIZAX. Recruitment of around 300 subjects is progressing well, and the trial is set to complete around the '26-'27 turn of the year, around January '27.

Peter Halling executive
#11

Assuming it gets the green light, ACARIZAX may reach mainland China in '28, and there the tablet would join the lineup sold by Grand Pharma, our new partner. A quick update on Japan as well: Torii, our partner there, is now a Shionogi subsidiary. Shionogi has stated its dedication to our tablet portfolio and views it as a core business pillar moving forward. The Phase 3 study of GRAZAX in Japan is ongoing and proceeding according to plan. Let's turn now to anaphylaxis and to commercialization of neffy, the nasal spray used for emergency treatment of acute allergic reactions, which carries the EURneffy brand in Europe. We brought EURneffy to Germany in June, and since then its market share has climbed steadily. That is encouraging for the product's longer-term potential, though it is still early days. EURneffy was also introduced in the UK a couple of weeks ago. Two of three key markets are now covered by us. Canada is the third market, and there the regulatory review remains pending, though it is moving ahead as planned. Further introductions, such as in Denmark, are imminent, and more launches are scheduled for '26. In every market where pricing and reimbursement have been finalized, EURneffy has obtained a price premium compared with adrenaline auto-injectors.

Peter Halling executive
#12

We also now have real-world evidence out of the US that backs up neffy's effectiveness being in line with that of adrenaline auto-injectors. In terms of user-friendliness, longer shelf life, and temperature stability, neffy offers advantages over auto-injectors. Even with these positive achievements, securing market access and changing long-standing clinical practices — such as the automated renewal of prescriptions for traditional anaphylaxis products — will most likely take some time. That said, the first indications we've seen in Germany and the positive feedback the medical community is giving us on this new treatment are encouraging. We will build on this positive feedback, work to change habits and behaviors, and furthermore allocate resources to pursue opportunities in other channels, including airlines and schools, to name a few. Moving to food allergy. The US FDA has granted a fast track designation to our peanut development program. This allows ALK to benefit from more frequent interactions with the FDA, and it highlights that the agency acknowledges that food allergy represents a significant unmet medical need. We expect this to support the timeline for the program. The ongoing Phase 2 trial with the peanut tablet in North America is on track to report topline data in the first half of '26, most likely towards Q2.

Peter Halling executive
#13

Meanwhile, work on planning for Phase 3 continues. So to wrap things up, overall we're seeing solid momentum in every disease area. With that, Claus, I'll turn things back over to you, and we'll move to slide eight.

Claus Steensen Sølje executive
#14

Thanks, Peter. Let's wrap up with the guidance for the year. As Peter mentioned earlier, we tweaked the full-year outlook a bit. We're now expecting revenue growth of 13% to 15% in local currencies, compared with the earlier guidance of 12% to 14% growth. Several factors underpin this new outlook: double-digit growth in tablet sales, driven by more patients and prescribers; single-digit growth in combined SCIT and SLIT-drops sales; and double-digit growth in sales of other products, particularly anaphylaxis. Back in the spring, we said the children indications and neffy launches would add roughly 1 percentage point to growth in 2025. Given what we've seen over the past quarter, we now think these two items will contribute 2% to 3% percentage points of the expected revenue growth. At the same time, we revised the EBIT margin outlook to around 26%, up from the 25% we previously anticipated. That works out to an improvement of 6 percentage points, driven by sales growth, gross margin improvements, and the optimizations. Also, we don't anticipate any one-offs this year, unlike last year, when one-offs totaled 75 million DKK. The new outlook implies total revenue growth of around 13% to 18% in Q4.

Claus Steensen Sølje executive
#15

We anticipate that the solid underlying momentum for tablets will carry on through Q4, with a robust influx of new patients during the current initiation season in Europe. That said, please be aware that tablet sales growth in Q4 is projected to be somewhat lower than during the first nine months, owing to the phasing of product shipments to Japan and possibly inventory fluctuation among European wholesalers. The Q4 EBIT margin is anticipated to come in below the level seen in the first nine months, which reflects what I noted earlier. We are directing an increasing share of funds toward growth initiatives such as the children launches, neffy, and the Phase 2 peanut trial. That covers new hires, which will result in higher capacity cost in Q4. Naturally, we will take these costs with us into 2026, though we will do so without putting our financial ambitions at risk. The 25% EBIT margin target for the coming years remains our expectation. In our view, the new outlook for 2025 strikes an adequate balance between risk and upsides. As such, we expect 2025 to be the seventh consecutive year of revenue growth and improved earnings, entirely consistent with ALK's long-term financial ambitions. With that, I would like to hand it back to Per and slide nine.

Per Plotnikof executive
#16

Thanks, Claus, and thanks, Peter. At this point we'll move on to the Q&A portion. Operator, would you please go ahead?

Operator operator
#17

Thank you. We’re moving into the question-and-answer portion now. If you’d like to ask something, press star followed by one on your touchtone phone. When you’re on a speakerphone, lift the handset first, then press the keys. Should your question be answered at any point and you wish to pull it, press star followed by two. Right now, we’ll take a brief pause while our roster is put together. Today’s first question is from Thomas Bowers at SEB. Please go ahead.

Thomas Bowers analyst
#18

Yes, thank you so much. I have a few questions, actually three of them. First, if we look at your new patients beginning in '25 — you're saying it's well above 10% with the tablet in '25. If you took out the pediatric indications' impact, would you still be above that 10% of new adults starting for this initiation season? Second, on gross margin — we're now seeing 2 percentage points year-over-year, which is quite impressive. How much of that comes from structural improvements, less scrapping and better yields, versus what you're seeing from product mix? And how should we think about gross margin improvements in '26? Will it be flat, or could we face some headwinds on product mix with Japan, China, and neffy? Any color would be appreciated. My final question for now is on R&D spend. What's driving the extreme back-end-loaded R&D spend implied for Q4 to get to that 10%? And regarding your midterm guidance or target of that 10% in '26 — is that still achievable given the quite strong top-line performance you have here?

Thomas Bowers analyst
#19

Since I’d imagine the bulk of any extra spending you put in tends to sit in sales and marketing, any detail on what you’re doing to hold that 25% EBIT would be welcome. Thank you.

Peter Halling executive
#20

Thanks, Thomas. Peter here. I'll begin with your question about patients, and Claus, perhaps you can chime in on gross margin, and one of us can address R&D spend too. Regarding the adults, we're expecting roughly 10%. Bear in mind it's still initiation season, we're still seeing the intake of patients and of course learning, but we anticipate it will land around 10%. Then on the first part of your question, yes, as we also mentioned, we saw a positive surprise when it comes to the intake of children. I think it's worth noting that part of why we've been somewhat conservative on this was we obviously had an assumption there might be this well-known ketchup effect, where you get a big inflow of people who have been waiting, but so far it has continued, especially with what we've seen on house dust mite. That has clearly been positive and has been pushing it upwards. That covers the patient side. On gross margin?

Claus Steensen Sølje executive
#21

Claus speaking — I’ll take that one. Thomas, that’s a good question, and you’re absolutely right that the gross margin improvement we’re seeing is better than we had anticipated. That is also the reason we’ve been able to raise the EBIT outlook. On your question about what is actually driving it: most of that 2%, if you look at it, is really coming from the volume mix of products here. We’re simply selling products that carry a higher margin. Then you might ask, what about the yield and scrap and variance improvements and so on? Those are there as well, but it’s important to understand that we also have the inflation increase on our production inputs into the manufacturing area. As things stand right now, we expect for this year that the increase in inflation to our manufacturing input is being counterbalanced by the improvements in the variances and the scrap and so on. Those two are actually offsetting each other, and that means the approximately 2% net that you then see comes from the product mix — selling more tablets at a higher margin. If you look into ’26 on that one, we are not guiding on ’26 right now.

Claus Steensen Sølje executive
#22

That's a little early. We'll handle that in February. I can add a bit more color to it. You're right that when we come out with improvements, as you can see here, of around 2%, then keep in mind we've normally stated that we want to raise gross margin by 0.5% to 1% year-on-year. That's the way we aim to improve gross margin year-on-year. Of course, given such a significant increase in '25, there could be some headwind next year. You're also pointing to the right reasons, actually, and that's precisely our partner markets. Next year, you'll see more shipments to Torii for lower margin products. You'll see now our partnership with Grand Pharma, which also carries a lower margin, and you'll also see growth in EURneffy sales, also at a lower margin in '26. Those three are, you could say, a drag on our gross margin. We'll still have higher tablet sales, don't worry. We'll also work on reducing scrap and on improvements in yield and variances. We'll have that as a counterbalance too, but it's a good idea to factor those partner markets and partners in when forecasting gross margin next year.

Peter Halling executive
#23

To go back over it, our long-term target is clearly that 25% EBIT, though we're deliberately choosing to put money into the business, consistent with what we said at Capital Markets Day. We're pleased both with where gross margin stands and with our capacity to exceed 25% on EBIT. On your final question about R&D spend, I can begin, and Claus and Per can also jump in on sales and marketing. Essentially, the rise you're seeing comes from trial activity. We mentioned China, and we mentioned peanut continuing, and so on, along with the investments in those. That's naturally climbing. We're getting ready for the next phases of the studies. In total, that's among the things pushing costs up. Long term we stated we'd land between 10% and 15%, but we also noted that 15% sits closer to the extreme end. You should expect more like 10% to 12% overall. Keep in mind that as Phase 3 trials arrive, R&D spend will obviously rise. Those are naturally costlier. Anything to add, Claus?

Claus Steensen Sølje executive
#24

No, I believe your point is spot on, and maybe I can just add that apart from the Phase 3 trials we're kicking off next year—and we're already beginning preparations for those even before we have the Phase 2 results, since we obviously feel confident about that—we have to start planning, and that will feed into the 2026 figures. Then you're correct. We'll also see growth in the commercial area next year, like what we'll see here in Q4: pediatric launches, EURneffy, and so forth. When you put together both the Phase 2 and Phase 3 next year plus the additional investments in our two very important commercial launches and activities for the remainder of this year and next year, we feel fairly comfortable about the long-term financial EBIT at around 25%. That remains the plan. I hope that clarifies things, Thomas, for all your questions.

Thomas Bowers analyst
#25

That's really excellent. Thank you. Perhaps I can follow up here regarding the possible spillover into the product mix remarks. I'm just curious about Japan. Shionogi has made some quite positive comments here recently. Of course, the standstill is in place. Is there anything we should look into with respect to product mix, because I suppose we could probably still see some low numbers in Japan already from the start of the year? Do you have any comments on when that standstill might potentially come to an end?

Peter Halling executive
#26

Thomas, the quick response is that growth in Japan is indeed something we expect to see, and the facility Torii is opening should become operational. In fact, we believe next year will be a strong year of growth in Japan. Clearly, timing plays a part in this, and that matters greatly to us as we move forward. When will CEDAR gain traction from the pass-through of API manufacturing? That is on its way, but we do observe things starting to come online. Shionogi has committed to the partnership and, just as certainly, to the market, so we are quite optimistic about the future trajectory in Japan.

Thomas Bowers analyst
#27

Thanks. I really appreciate it.

Operator operator
#28

Jesper Ingildsen from DNB Carnegie has the next question. Go right ahead.

Jesper Ingildsen analyst
#29

Thanks. There are also three things I'd like to ask. First, going back to the pediatric launch: you're now pointing to a contribution of 1 to 2 percentage points from that launch this year. Given the momentum you're seeing and the ongoing rollout, could you give some color on what we should expect as we head into next year — I suppose this overlaps somewhat with Thomas's question regarding new patient starts. I know you've touched on that a bit already, but any additional detail would help. Second, on neffy: ARS Pharma said the other day that the German launch has gotten off to a strong start. I believe they even noted that market share capture in just the first few months was three times higher than what they'd seen in the US. Could you add some color on that launch and, in your view, what might be driving the faster share gain relative to the US? Finally, on capital allocation: the balance sheet is clearly looking stronger and stronger. Any update on what we should expect there regarding buybacks, dividends, and M&A more broadly.

Jesper Ingildsen analyst
#30

How do you see things right now? Thank you.

Peter Halling executive
#31

Thanks, Jesper. This is Peter. I'll begin with the first two, and Claus, if you'd handle capital allocation, feel free to jump in at any point. Regarding the first one, since we can't provide guidance for next year — clearly, we've raised our view of what we saw on the peat side this year. As we also mentioned, that's mainly being driven by ACARIZAX. The ongoing stream of patients we've seen is obviously positive. In terms of getting data early in the ITULAZAX initiation season, we're positive. We've witnessed a solid influx, though I think it's too early to say much more about that one right now. I'll simply note that, overall, we remain positive, also because of the 3,000 unique or new prescribers we've seen come in. Positive overall. I'd just caution that data is still arriving, and we need to become much wiser on that one. That's all we can say. Then, on neffy and ARS's remark about Germany: it's true that we've seen a good start in Germany. What matters most at the moment is very much market access. It's very much about making sure we also have an inflow, or that we make a move into the automated renewals.

Peter Halling executive
#32

A lot of the current market sits right there, and we have to keep our attention on it. What we're seeing in Germany is encouraging, both the uptake and the share gain we've achieved up to now — a smaller-volume market, admittedly — but the prescriber mix also looks encouraging, with strong growth among general practitioners, who aren't where our people go in person. Our online and digital work has paid off, and the same holds in other prescriber groups. That's clearly a plus. Again, particularly since it's early days and volumes in smaller markets tend to fluctuate somewhat, I'd caution that we'll see some swings, of course. Having said that, ARS — and we value their positive view — and it's genuinely good to see so far. I'll stop there. Claus, shall we turn to capital allocation?

Claus Steensen Sølje executive
#33

Yes, thank you for that question, Jesper. It's a good one. As we've mentioned before, there's no question that this year stands out as quite unusual for ALK when it comes to our cash position. Looking back a few years, cash wasn't a major issue for us, since we didn't hold very much of it. This year, we're guiding toward more than a billion in free cash flow, which ties of course to significantly higher sales, the gross margin, and the EBIT we're delivering. A strong year this time around. As for how we'll deploy it and how we're thinking about that, we've already communicated our long-term financial targets, and when we introduced the new Allergy+ strategy at our Capital Markets Day, we said that first we'd like to put investment into our commercial opportunities: the children, the neffy, and so on, and then into R&D. We'll of course also put investment into tablet manufacturing and make sure we're investing there for the future. At the moment, we have capacity. We're producing 300 to 400 million tablets each year. We can go up to 800, and we need to make sure we can keep delivering the millions and soon billions of tablets to the market.

Claus Steensen Sølje executive
#34

There are also, as we've said, things happening on the BD, business development side. You saw the neffy collaboration, and you saw the China one. There may be some activities in that area that we'd want to put money into. So once we've reviewed all of that, we've also stated very clearly that we don't intend to be a bank. We won't just sit on cash on the balance sheet for a long stretch. If we reach a point where we can't deploy our own incoming cash flow, including what's already in the bank, on the items I just listed, then naturally we're looking at dividends, share buybacks, or whatever form it takes. That will of course be a discussion with the board around the annual general assembly here, and we'll come back with an answer at that point. I hope that explains it, Jesper.

Jesper Ingildsen analyst
#35

Yeah, thanks.

Operator operator
#36

Just a quick reminder — if you'd like to ask a question, hit star followed by one to get into the queue. Our next question is from Sushila Hernandez at Van Lanschot Kempen. Go right ahead.

Sushila Hernandez analyst
#37

Yes, thanks for taking my question. It's also about neffy. You said that in Germany, clinical practice has long favored traditional adrenaline products. How do you plan to shift away from that? And could you also give any color on how things look for the UK market? Thank you.

Peter Halling executive
#38

Alright, let me begin with neffy. First off, thank you for that question—it’s a good one. I’ll try to pull it back a bit. What we’re clearly observing is that prescribers follow a pattern of automated renewal. From the patient’s side, you call once each year and receive your renewal for the adrenaline pen. With a new product now entering the picture, what we’re seeing is that not only the physician but the entire practice must be educated, and you have to get into the system—this also includes making sure the patient has an understanding and has seen the product. That’s part of shifting the prescription patterns that already exist. On top of that, there’s the whole wave of new patients generated by patient awareness, considerable interest from doctors regarding new products, and so forth. That’s precisely where we have a major focus. It means making sure there is education, training for doctors, KOLs, and others, making sure we’re on hand at conferences, and also that the public has general awareness. This ties back to what I said about the digital effort, where we’re placing a great deal of emphasis. And then, of course, with the nurses and other practitioners—that’s where our team maintains an ongoing conversation with the clinics, and we make sure both KOLs and others take part in the training.

Peter Halling executive
#39

That applies not just to Germany but to every market where we operate. That's what I'd say regarding neffy. Per, go ahead.

Per Plotnikof executive
#40

Perhaps I should bring the UK into this as well, since that was part of what you asked about. We have launched there. Pricing has been secured, and the next thing now is to ensure it's anchored in the local formulary listings too. That will be the main focus over the months ahead in the UK. Before we have any sense of how it performs there, realistically we're into next year, particularly given that we're heading into the low season — the traditional low season for anaphylaxis products in Europe. In the near term, the emphasis really is on making sure it's anchored within the local Integrated Care Trusts and systems on the formularies. Does that answer your question?

Sushila Hernandez analyst
#41

Appreciate it. That is clear.

Operator operator
#42

That brings our question-and-answer session to a close. I'd like to hand the conference back for any closing remarks.

Per Plotnikof executive
#43

Thanks, operator, and I appreciate the thoughtful questions. Ahead of wrapping up, I want to point you toward our Q3 roadshows — that takes us to Copenhagen, to Canada, to London, Oslo, and so on. We very much hope to catch you at some of those events. And as ever, you're more than welcome to reach out to either of us should anything else come up. With that, we'll close out today's session, and we wish everyone a good day. Many thanks.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete ALK-Abelló A/S transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to ALK-Abelló A/S earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.